The Technical Analyst
Select Language :
Zai Lab Ltd [ZLAB]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Zai Lab Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

Zai Lab Ltd is listed at the  Exchange

-1.05% $16.02

America/New_York / 28 mar 2024 @ 16:00


FUNDAMENTALS
MarketCap: 1 581.45 mill
EPS: -3.50
P/E: -4.58
Earnings Date: May 06, 2024
SharesOutstanding: 98.72 mill
Avg Daily Volume: 0.666 mill
RATING 2024-03-28
B+
Neutral
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Sell
Return On Asset: Neutral
DE: Sell
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -4.58 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.78x
Company: PE -4.58 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 14.79 - 17.25

( +/- 7.66%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-15 Amado Rafael Sell 2 544 American Depositary Shares
2024-03-15 Edmondson Frazor Titus Iii Sell 10 000 American Depositary Shares
2024-03-13 Du Ying Sell 33 030 American Depositary Shares
2024-03-13 Du Ying Sell 861 American Depositary Shares
2024-03-01 Smiley Joshua L Buy 3 000 American Depositary Shares
INSIDER POWER
33.05
Last 100 transactions
Buy: 2 102 572 | Sell: 988 719

Forecast: 16:00 - $15.98

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $15.98
Forecast 2: 16:00 - $15.98
Forecast 3: 16:00 - $15.98
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $16.02 (-1.05% )
Volume 0.780 mill
Avg. Vol. 0.666 mill
% of Avg. Vol 117.15 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Zai Lab Ltd

Last 12 Months

Last 12 months chart data with high, low, open and close for Zai Lab Ltd

RSI

Intraday RSI14 chart for Zai Lab Ltd

Last 10 Buy & Sell Signals For ZLAB

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35sell$19.51N/AActive
Profile picture for
            Zai Lab Ltd

ZLAB

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.

Last 10 Buy Signals

Date Signal @
FLIPUSDMar 29 - 10:055.04
SCNSOLUSDMar 29 - 09:59220.06
INVUSDMar 29 - 09:5963.18
SUPERUSDMar 29 - 09:34$1.359
UQCUSDMar 29 - 06:54$7.20
BNBUSDMar 29 - 09:31$615.19
TIMEUSDMar 29 - 09:3232.37
AGLDUSDMar 29 - 09:301.650
MINAUSDMar 29 - 09:29$1.238
CBKUSDMar 29 - 09:281.087

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.